Bachy et al reported a score for evaluating a patient with de novo follicular lymphoma who is treated initially with immunochemotherapy. This can help to identify a patient who may benefit from more aggressive management. The authors are from multiple institutions from around the world.
Patient selection: follicular lymphoma initially treated with immunochemotherapy
Outcome: progression-free survival (PFS)
Parameters:
(1) serum beta-2 microglobulin in mg/L
(2) bone marrow involvement
beta-2 microglobulin
Bone Marrow Involved
Risk Category
<= 3 mg/L
no
low
<= 3 mg/L
yes
intermediate
> 3 mg/L
NA
high
Risk Category
5-Year PFS
low
69%
intermediate
55%
high
37%
In addition, achieving event-free survival at 24 months after starting therapy predicted a good overall survival.
To read more or access our algorithms and calculators, please log in or register.
